北京毅新博创生物科技有限公司

400-6699-117转1000
热门搜索:
分析测试百科网 > 毅新质谱 > 资料下载 > Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer

Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer

发布时间: 2016-02-19 15:00 来源:北京毅新博创生物科技有限公司
领域: 蛋白/抗体/蛋白质组
资料类型:NONE

下载地址2:Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer


  Abstract

  No ideal serum biomarker currently exists for the early diagnosis of colorectal cancer (CRC). Magnetic bead-based fractionation coupled with MALDI-TOF MS was used to screen serum samples from CRC patients, healthy controls, and other cancer patients. A diagnostic model with 5 proteomic features (m/z 1778.97, 1866.16, 1934.65, 2022.46 and 4588.53) was generated using Fisher algorithm with best performance. The Fisher-based model could discriminate CRC patients from the controls with 100% (46/46) sensitivity and 100% (35/35) specificity in the training set, 95.6% (43/45) sensitivity and 83.3% (35/42) specificity in the test set. We further validated the model with 94.4% (254/269) sensitivity and 75.5% (83/110) specificity in the external independent group. In other cancers group, the Fisher-based model classified 25 of 46 samples (54.3%) as positive and the other 21 as negative. With FT-ICR-MS,the proteomic features of m/z 1778.97, 1866.16, 1934.65 and 2022.46, of which intensities decreased significantly in CRC, were identified as fragments of complement C3f. Therefore, the Fisher-based model containing 5 proteomic features was able to effectively differentiate CRC patients from healthy controls and other cancers with a high sensitivity and specificity, and may be CRC-specific. Serum complement C3f, which was significantly decreased in CRC group, may be relevant to the incidence of CRC.


移动版: 资讯 直播 仪器谱

Copyright ©2007-2023 ANTPEDIA, All Rights Reserved

京ICP备07018254号 京公网安备1101085018 电信与信息服务业务经营许可证:京ICP证110310号